Carcinoma hepatocelularFase 1NCT05003895
Células CAR-T
Terapia con células CAR-T dirigidas contra GPC3 en tumores sólidos malignos avanzados que expresan GPC3
Vacuna peptídica contra la quinasa de fusión DNAJB1-PRKACA combinada con nivolumab e ipilimumab para pacientes con carcinoma hepatocelular fibrolamelar
Lo que dice el vídeo
Most liver cancer is the end of a long story. Decades of hepatitis, or alcohol, or fatty liver, scarring the organ until something breaks.
Fibrolamellar carcinoma is not that story. It turns up in teenagers and young adults with healthy livers and no risk factors at all. In this trial the median age was twenty-four, and the youngest patient twelve. It is rare: recent work estimates about six hundred new cases a year in the United States. Surgery can cure it, if the whole tumor can be removed. If it cannot, there is no standard drug treatment, and half of those patients live about a year.
But this cancer has an unusual feature. Its cause is known, and it is a single event.
In twenty fourteen, researchers sequenced these tumors and found that a stretch of chromosome nineteen, about four hundred thousand letters long, had gone missing. The deletion pulled two neighboring genes together and fused them into one. One makes a chaperone, a protein that helps other proteins fold. The other makes the working half of an enzyme called protein kinase A. Joined, they make a hybrid that still works as an enzyme, and that hybrid drives the cancer. It was in all fifteen tumors they examined, and in none of the normal liver beside them.
So block the hybrid enzyme. That was the obvious move, and it failed. Protein kinase A is essential everywhere in the body, and the drugs were too toxic to use. The field called the target undruggable.
Which leaves a different approach. Do not attack the protein. Point at it.
Where the two genes join, the protein has a seam, a short run of amino acids that exists in no healthy cell in the body. To the immune system, that seam looks foreign. So the vaccine in this trial is simply that seam. A peptide twenty-four amino acids long, made in a lab, injected under the skin alongside something that tells the immune system to pay attention.
Two things make this seam remarkable. The tumor cannot drop it, because it is the engine. And because the break always falls in the same place, the seam is identical from patient to patient. One vaccine fits everyone with this disease.
The vaccine raises T cells. A tumor can still switch them off, so it is given with two antibodies, nivolumab and ipilimumab, that release the brakes on T cells.
The first results came out in twenty twenty-five. Sixteen patients enrolled and twelve finished the vaccine course. Nine of the twelve developed T cells that recognized the seam, where only one had them at the start. Nine had their disease held in check, and three tumors shrank by at least a third. Every patient who responded also developed those T cells, which is the link the trial was built to test. A thirteen-year-old was still responding after two years. Side effects were mostly sore injection sites, headache and fatigue, though about a third of patients had a more serious reaction to the antibodies.
And when the cancer did escape, the tumor had not hidden the seam. The T cells had worn out, which is a different and more tractable problem.
The trial continues at Johns Hopkins, led by Mark Yarchoan, and now includes other cancers that carry the same fusion.
Everything in this film comes from the published record, and it is not medical advice.
Fuentes de este vídeo
Honeyman JN. Science, 2014
Most liver cancer follows decades of hepatitis, alcohol or fatty liver; fibrolamellar does not; A stretch of chromosome nineteen about four hundred thousand letters long went missing, fusing two neighboring genes; One gene makes a chaperone; the other the working half of protein kinase A; joined they still work as an enzyme; In all fifteen tumors examined, in none of the normal liver beside them (+1 more lines)
Most liver cancer follows decades of hepatitis, alcohol or fatty liver; fibrolamellar does not
Baretti M. Nat Med, 2025
Median age twenty-four in this trial; youngest patient twelve; No standard drug treatment; half of those patients live about a year; Blocking the enzyme failed; protein kinase A is essential everywhere; the target was called undruggable; The seam exists in no healthy cell; the vaccine is that seam, twenty-four amino acids, injected with something that gets the immune system's attention (+11 more lines)
Median age twenty-four in this trial; youngest patient twelve; Surgery can cure it if the whole tumor can be removed; Sixteen enrolled, twelve finished the course; Mostly sore injection sites, headache, fatigue; about a third had a more serious reaction to the antibodies (+1 more lines)
Zack T. NPJ Precis Oncol, 2023
About six hundred new US cases a year
Glavas D. J Gastrointest Surg, 2023
Surgery can cure it if the whole tumor can be removed
Surgery can cure it if the whole tumor can be removed
El fármaco
1. Vacuna peptídica DNAJB1-PRKACA: días 1, 8 y 15 del ciclo 1 y día 1 de los ciclos 2, 3 y 4 (fase de sensibilización). Vacunas de refuerzo: cada 3 ciclos a partir del C5D1.
1. Nivolumab 3 mg/kg se administrará en infusión IV de 30 minutos (-10/+15 min) el día 1 de los ciclos 1 a 4 durante la fase de sensibilización. Las vacunas de refuerzo/mantenimiento se administrarán con una dosis fija de 480 mg cada 4 semanas a partir del día 1 del ciclo 5.
El estudio
El objetivo principal del ensayo es la seguridad y la tolerabilidad de administrar una vacuna dirigida contra la quinasa de fusión DNAJB1-PRKACA, en combinación con nivolumab e ipilimumab, en pacientes con CHF irresecable o metastásico y con tumores sólidos no CHF, y evaluar la respuesta de las células T.
Requisitos
Criterios de inclusión tal como figuran en el registro, recortados. La lista completa, con las exclusiones, está en el registro actualizado.
Para ti, o para alguien a quien quieres
Un diagnóstico complejo trae preguntas nuevas cada semana, dentro de un ensayo y fuera de él. Triangle reúne todo tu expediente médico, lo lee contigo en lenguaje claro y te ayuda, a ti y a tu familia, a decidir qué preguntar después.
Después, $9 al mes. Cancela cuando quieras.
Solicitados a tus hospitales y clínicas a través de las redes nacionales. Añade estudios de imagen, patología y cualquier documento en papel.
Informes explicados a medida que llegan, con valores de laboratorio que puedes seguir antes del tratamiento, durante un ensayo y después.
Pregunta sobre tu propio expediente y llega con preguntas para tu oncólogo o el equipo del ensayo.
Comparte un mismo perfil con la familia que te ayuda y con tus médicos.
Los miembros también reciben un análisis profundo de sus historiales y de cualquier dato de secuenciación, incluidos los ensayos clínicos que podrían encajar, revisado por un médico colegiado antes de recibirlo.
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.